28 Sep 2026, 08:45 IST
Zydus Lifesciences Limited
Motilal Oswal Financial Services Ltd.
The report states a USFDA inspection of Zydus's pharmacovigilance systems concluded with nil observations and highlights the company's industry-outperforming growth and FY27 guidance of double-digit revenue growth with ~24% EBITDA margin.
From MOStMarketOutlook28092026, written by Motilal Oswal Financial Services Ltd. and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd.'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.